Turning RNA Interference Research into Medicines

The approval of the first siRNA-based therapeutic this year has opened the door for companies to pursue expansion of this class of medicines. Deal activity, the progress of academics, and a favorable regulatory environment in Japan have contributed to interest in the field. This session will provide updates on current approaches and techniques for this pipeline of therapeutics.